Executive summary
According to Peter Attia, MD on The Drive, accurate home blood pressure monitoring—modeled on the SPRINT trial's rigorous methodology—may be a higher-leverage longevity lever than most supplement stacks, since each 20mmHg rise in systolic pressure is associated with a doubling of stroke/CVD/vascular death risk. We also cover Mark Hyman, MD's breakdown of the 'fiber maxing' trend and its endogenous GLP-1 mechanism, Dr. Lisa Boardman's updated colorectal cancer screening protocol on Mayo Clinic's podcast, and Dr. Jared Rutter's mitochondrial metabolism discussion with Andrew Huberman.
Key takeaways
- Home blood pressure monitoring, done with SPRINT-trial rigor (3-5 min rest, 3 readings averaged, 2-3 weeks of data before acting), may be a higher-leverage intervention than most supplement stacks—each 20mmHg rise in systolic pressure is linked to a doubling of stroke/CVD death risk per Peter Attia, MD.
- Ramp dietary fiber toward 30-50g/day from diverse whole foods at roughly 5g/week, per Mark Hyman, MD—fermentable fiber's conversion to butyrate may stimulate endogenous GLP-1 signaling, but pair it with adequate protein and watch thyroid medication timing.
- Colorectal cancer screening now starts at 45, not 50, per Dr. Lisa Boardman—early-onset incidence has more than doubled since 1987, making this one of the highest-ROI calendar reminders you can set this month.
THE DAILY OPTIMIZER
Today's signal centers on a lever nearly every optimizer already owns but few measure correctly: blood pressure. According to Peter Attia, MD on The Drive podcast, home BP monitoring done with the same rigor as the SPRINT trial's protocol may outperform most supplement stacks in risk-reduction value per unit of effort—a useful reminder before chasing the next exotic peptide. We pair that with Mark Hyman, MD's breakdown of the 'fiber maxing' trend and its connection to endogenous GLP-1 signaling, Dr. Lisa Boardman's updated colorectal cancer screening protocol (now starting at age 45) from Mayo Clinic, and Dr. Jared Rutter's mechanistic walkthrough of mitochondrial pyruvate handling on the Huberman Lab podcast. Rounding out the brief: Dr. Alex Tatem's evidence review of modafinil's real cognitive effect size, a cardiac electrophysiology case series that complicates the 'higher HRV is always better' heuristic, and a preview of Stanford organ-aging research discussed by Dr. Will Cole. Each item below comes with specific dosing, thresholds, and tracking metrics you can act on today.
DEEP DIVE: THE BLOOD PRESSURE PROTOCOL YOU'RE PROBABLY MEASURING WRONG
Let's start with the mechanism, because it explains why this matters as much as lipids do. According to Peter Attia, MD, hypertension is a mechanical endothelial insult—distinct from the chemical damage of smoking or the particle-infiltration mechanism of elevated ApoB—and it disproportionately damages three high-flow organ systems: the heart (which perfuses during diastole, making diastolic pressure more consequential than commonly appreciated), the brain, and the kidneys, which receive 20-25% of cardiac output despite being only 1-2% of body mass. The evidence base is anchored in the SPRINT trial (Attia's primary reference): roughly 10,000 high-ASCVD-risk subjects without type 2 diabetes were randomized to an intensive systolic target of <120 versus a standard target of <140. At one year, the intensive arm achieved 121.4 systolic versus 136.2 in standard care, producing a 25% relative reduction in the composite cardiovascular outcome and a 27% relative reduction in all-cause mortality. A companion sub-study, SPRINT MIND, found a 16% relative reduction in dementia risk under intensive control. The 2021 STEP trial replicated the cardiovascular benefit in Chinese adults aged 60-80 (26% reduction in composite CV outcomes) but notably found no all-cause mortality benefit—an important nuance Attia flags rather than glosses over. Here is the protocol Attia actually uses: sit quietly for 3-5 minutes with back supported, feet flat, arm at heart level, bladder empty (a full bladder can add 10-15 points), cuff on bare skin. Take three readings five minutes apart and average them. Repeat this twice daily for 2-3 weeks before making any treatment decision—never act on a single day's number. Attia notes his own automated cuff readings run 10-15mmHg higher than manual auscultation performed by multiple independent people; his practical fix is to use automated cuffs to build the habit but periodically validate against a manual reading. On the lifestyle side, the levers are quantified: weight loss delivers roughly 1mmHg systolic and diastolic reduction per kilogram lost; aerobic exercise (90-150 min/week at 65-75% max heart rate) can reduce systolic up to 8mmHg; isometric resistance training shows an outsized effect (systolic -6mmHg) despite transient spikes during the lift itself. Sodium reduction is genuinely heterogeneous by individual salt-sensitivity—extreme restriction below 1.5g/day lowered systolic 5-6mmHg in one meta-analysis but was paradoxically associated with increased all-cause mortality, so Attia explicitly warns against over-restriction.
METRICS & MEASUREMENT
Track your BP against the 2017 ACC/AHA thresholds: Normal is systolic <120 and diastolic <80; Elevated is 120-129/<80; Stage 1 hypertension begins at 130-139 OR 80-89; Stage 2 at ≥140 OR ≥90 (per Attia's review of ACC/AHA guidance). A meaningful intervention response is a sustained 5-10mmHg drop across a 2-3 week averaged measurement window—not a single reading. For kidney-specific surveillance, Attia tracks Cystatin C over creatinine, and flags a GFR of 60 as normal for someone over 75 but a red flag at age 50-55. If you're layering in metabolic tracking, pair this with fasting insulin and HOMA-IR (target near 1.0; ≥2.0 flags resistance, per the presenter on Dr. Suneel Dhand's channel) and, for cardiovascular risk stratification broadly, ApoB and Lipoprotein(a)—both cited repeatedly across today's sources as chronically under-tested.
THE LONGEVITY TOOLKIT
This week's toolkit pick: a validated upper-arm automated BP monitor, cross-checked periodically against manual auscultation. As Peter Attia's own n=1 data shows, automated cuffs can run systematically 10-15mmHg high due to algorithmic mean-arterial-pressure back-calculation rather than true two-phase measurement—so the device alone isn't the protocol, the validation habit is. Buy a cuff sized correctly to your arm circumference, calibrate your expectations with a manual reading from a clinician at least once, then run the twice-daily, three-reading averaging protocol described above for 2-3 weeks before drawing any conclusion. This is the rare biomarker tool that costs under $50 and outperforms far more expensive wearables for actionable, dose-response-relevant cardiovascular data.
FUEL & RECOVERY
On the nutrition side, Mark Hyman, MD's guidance on 'fiber maxing' is directly actionable this week: target 30-50g of fiber daily from diverse whole foods (lentils, chia, flax, artichokes, berries) rather than maxing out one isolated supplement—his framing is that 30g of varied plant fiber outperforms 60g from a single source. Ramp gradually, adding roughly 5g per week to avoid bloating and gas, since most Americans start near half the target intake. Fermentable fiber is metabolized by colonic bacteria into short-chain fatty acids like butyrate, which Hyman states strengthens the gut lining and may stimulate endogenous GLP-1 release—the same appetite-regulating pathway targeted by pharmaceutical GLP-1 agonists, just via your own biology. Two non-negotiables: pair every fiber-forward meal with adequate protein to avoid muscle loss, and if you're on thyroid medication, separate dosing timing from high-fiber meals to protect absorption.
SIGNAL ROUNDUP: SEVEN MORE DEVELOPMENTS WORTH YOUR ATTENTION
Per Dr. Lisa Boardman on Mayo Clinic's podcast, average-risk adults should begin CRC screening at age 45 (down from 50), given that early-onset incidence has more than doubled since 1987 (4.5 to 9.4 per 100,000) and CRC is now the #1 cause of cancer death in men under 50. Colonoscopy every 10 years, FIT testing annually, or stool DNA/FIT combo every 3 years are all guideline-acceptable options; any positive non-colonoscopy result mandates a follow-up colonoscopy. **Mitochondria make resource-allocation decisions, not just energy.** According to Dr. Jared Rutter on the Huberman Lab podcast, every cell decides whether to burn pyruvate for ATP or redirect it toward biomass production via the mitochondrial pyruvate carrier (MPC1/MPC2)—a mechanism Rutter's lab helped identify. This reframes why fasting and ketogenic protocols work: they shift glucagon-dominant signaling to mobilize fatty acids, sparing glucose for the brain. **Modafinil's cognitive boost is real but tiny in well-rested adults.** Per Dr. Alex Tatem, a 2019 meta-analysis of 19 placebo-controlled trials found an effect size (Hedges' g) of just 0.10 in non-sleep-deprived healthy adults—versus dramatically larger benefits during sleep deprivation (one military study maintained performance through 64 hours awake on 100mg every 8 hours). A 2024 military pilot study also found modafinil users became overconfident about their own performance. **Statin decisions should be biomarker-driven, not blanket.** Two physicians on Dr. Suneel Dhand's channel argue secondary prevention (post-heart attack) statin evidence is strong, while primary prevention benefit is comparatively small—recommending the lowest effective dose and a 6-12 month reassessment checkpoint tied to ApoB, Lp(a), and inflammatory markers rather than automatic dose escalation. **High HRV isn't always the goal.** Per Dr. Guru Kolgi, a Mayo Clinic electrophysiologist who has performed roughly 120 cardio-neuroablation cases, patients with vagal-predominant syncope actually benefit from a *reduction* in HRV post-procedure—a useful corrective to oversimplified wearable-driven HRV narratives. **Morning light exposure anchors more than mood.** According to Dr. Meenal Agarwal on Resiliency Radio, the eye is the only site that sets circadian rhythm via the suprachiasmatic nucleus—morning light exposure triggers downstream dopamine release, making it a foundational (not optional) daily input. **Peptide and HBOT protocols remain n=1, high-risk territory.** Dr. Josh Axe's account of recovering from a rare spinal infection (roughly 4 per million cases, per his own research) using hyperbaric oxygen therapy plus a BPC-157/TB-500 peptide stack is a compelling case study, but it's a single self-reported outcome, not validated protocol data—treat it as hypothesis-generating, not a template to copy without physician oversight.
Sources
- Peter Attia MD (The Drive podcast)
- Mark Hyman, MD
- Andrew Huberman / Dr. Jared Rutter (Huberman Lab)
- Mayo Clinic (Dr. Lisa Boardman, colorectal cancer)
- Mayo Clinic (Dr. Guru Kolgi, cardio-neuroablation)
- Dr. Alex Tatem (modafinil)
- Dr. Suneel Dhand (statins and insulin resistance)
- Dr. Jill Carnahan / Dr. Meenal Agarwal (Resiliency Radio)
- Dr. Will Cole / Dr. Josh Axe (The Art of Being Well)